$ cat ./records/gates-foundation-invests-40-million-to-accelerate-mrna-vaccine-ma-2023.txt
Gates Foundation Invests $40 Million to Accelerate mRNA Vaccine Manufacturing in Africa
[RECORD.TXT] · cat --full
At the Grand Challenges Annual Meeting in Dakar, Senegal, Gates announced $40 million in new investments to build mRNA vaccine manufacturing capacity in lower-income countries: $20 million to Quantoom Biosciences (Belgium) to develop its low-cost mRNA platform, and $5 million each to Institut Pasteur de Dakar (Senegal) and Biovac (South Africa) to deploy the technology locally. Gates described mRNA technology as a potential 'game-changer' for diseases including tuberculosis, malaria, and Lassa fever. The initiative built on the foundation's prior $55 million BioNTech investment and sought to ensure Africa could manufacture its own mRNA vaccines for future outbreaks.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
R21/Matrix-M malaria vaccine receives first national regulatory approval — in Ghana
Next →
Gates Meets President Xi Jinping; Foundation Pledges $50 Million to Tsinghua Drug Discovery Institute
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.